Also, I find this simultaneously fascinating and hard to believe.

For now, we’ll likely run LymphGen and DLBclass in parallel. We may see the integration of different modalities (e.g., transcriptional, microenvironmental, proteomic, epigenetic) reveal new subtypes or refine existing ones. 3/3

DLBclass subtypes 100% of cases, while LymphGen leaves ~40% unclassified. Forcing assignments risks diluting molecular purity affecting potential personalised clinical trials, but failing to assign a subtype may miss a therapeutic opportunity. 2/3

From "The Novel and its Critics in the Early Nineteenth Century" by Michael Munday; Studies in Philology, Vol. 79, No. 2 (Spring, 1982)

What an interesting statement! In principle, not observing something as a trend or event doesn’t preclude its existence. We can debate if truth-finding is overly hypothesis-driven (think, „can a biologist fix a radio”), but I agree, the thinking process remains broadly similar with good outcomes.

Orb 🏀